ArticleCancer2023

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.

Ajay K Nooka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.